Vol 2003, No 40 (2003)

Table of Contents

Research & Development

Merck Backs Alnylam’s RNAi Technology Abstract pdf
Business Review Editor

Licensing

Aventis and Regeneron Enter Collaboration for VEGF Trap Abstract pdf
Business Review Editor
Bristol-Myers Squibb Licenses Flamel’s Basulin® Abstract pdf
Business Review Editor
Amgen Enters metabolic Disease Market with Biovitrum Deal Abstract pdf
Business Review Editor

General

Medivir and Boehringer Ingelheim in HIV Deal Abstract
Business Review Editor
The problem with Antibiotics Abstract
Business Review Editor
Therapy Focus: Severe Acute Respiratory Syndrome Abstract
Business Review Editor

Mergers & Acquisitions

Xenova Acquires KS Biomedix to Focus on Brain Cancer Drug Abstract pdf
Business Review Editor

Company Profile

Acambis plc Abstract pdf
Business Review Editor
Genestream Pty Ltd Abstract pdf
Business Review Editor


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.